HK1151038A1 - Kdr peptides and vaccines comprising the same kdr kdr - Google Patents

Kdr peptides and vaccines comprising the same kdr kdr

Info

Publication number: HK1151038A1
Authority: HK; Hong Kong
Prior art keywords: kdr; peptides; vaccines; same; amino acid
Prior art date: 2002-09-12

Application number

HK11104995.4A

Other languages

English (en)

Chinese (zh)

Inventor

Hideaki Tahara

Satoshi Wada

Takuya Tsunoda

Original Assignee

Oncotherapy Science Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-09-12

Filing date

2009-05-15

Publication date

2012-01-20

2009-05-15 Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc

2012-01-20 Publication of HK1151038A1 publication Critical patent/HK1151038A1/xx

Links

102000004196 processed proteins & peptides Human genes 0.000 title abstract 6
108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
229960005486 vaccine Drugs 0.000 title abstract 2
125000003275 alpha amino acid group Chemical group 0.000 abstract 3
239000003814 drug Substances 0.000 abstract 2
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
150000001413 amino acids Chemical class 0.000 abstract 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4203—Receptors for growth factors
- A61K40/4208—Vascular endothelial growth factor receptors [VEGFR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/50—Colon
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Diabetes (AREA)
Oncology (AREA)
Mycology (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Dermatology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Cardiology (AREA)
Hematology (AREA)
Obesity (AREA)
Toxicology (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)

HK11104995.4A 2002-09-12 2009-05-15 Kdr peptides and vaccines comprising the same kdr kdr HK1151038A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2002267285		2002-09-12
JP2003062003		2003-03-07
JP2003167042		2003-06-11

Publications (1)

Publication Number	Publication Date
HK1151038A1 true HK1151038A1 (en)	2012-01-20

Family

ID=31998762

Family Applications (7)

Application Number	Title	Priority Date	Filing Date
HK09104058.2A HK1124077A1 (en)	2002-09-12	2009-04-30	Kdr peptides and vaccines comprising the same
HK11104992.7A HK1151036A1 (en)	2002-09-12	2009-05-15	Kdr peptides and vaccines comprising the same kdr kdr
HK11104995.4A HK1151038A1 (en)	2002-09-12	2009-05-15	Kdr peptides and vaccines comprising the same kdr kdr
HK11104977.6A HK1151032A1 (en)	2002-09-12	2009-05-15	Kdr peptides and vaccines comprising the same kdr kdr
HK11104996.3A HK1151039A1 (en)	2002-09-12	2009-05-15	Kdr peptides and vaccines comprising the same kdr kdr
HK09104475.7A HK1125659A1 (en)	2002-09-12	2009-05-15	Kdr peptides and vaccines comprising the same kdr
HK11104993.6A HK1151037A1 (en)	2002-09-12	2009-05-15	Kdr peptides and vaccines comprising the same kdr kdr

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
HK09104058.2A HK1124077A1 (en)	2002-09-12	2009-04-30	Kdr peptides and vaccines comprising the same
HK11104992.7A HK1151036A1 (en)	2002-09-12	2009-05-15	Kdr peptides and vaccines comprising the same kdr kdr

Family Applications After (4)

Application Number	Title	Priority Date	Filing Date
HK11104977.6A HK1151032A1 (en)	2002-09-12	2009-05-15	Kdr peptides and vaccines comprising the same kdr kdr
HK11104996.3A HK1151039A1 (en)	2002-09-12	2009-05-15	Kdr peptides and vaccines comprising the same kdr kdr
HK09104475.7A HK1125659A1 (en)	2002-09-12	2009-05-15	Kdr peptides and vaccines comprising the same kdr
HK11104993.6A HK1151037A1 (en)	2002-09-12	2009-05-15	Kdr peptides and vaccines comprising the same kdr kdr

Country Status (14)

Country	Link
US (5)	US7514084B2 (xx)
EP (11)	EP2261248B1 (xx)
JP (3)	JP3971769B2 (xx)
CN (5)	CN100352843C (xx)
AT (2)	ATE432291T1 (xx)
AU (1)	AU2003264419A1 (xx)
CY (2)	CY1109463T1 (xx)
DE (1)	DE60327786D1 (xx)
DK (6)	DK2267021T3 (xx)
ES (2)	ES2327040T3 (xx)
HK (7)	HK1124077A1 (xx)
PT (2)	PT1548032E (xx)
SI (2)	SI1548032T1 (xx)
WO (1)	WO2004024766A1 (xx)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2327040T3 (es)	2002-09-12	2009-10-23	Oncotherapy Science, Inc.	Peptidos kdr y vacunas que los contienen.
US9090673B2 (en) *	2003-12-12	2015-07-28	City Of Hope	Synthetic conjugate of CpG DNA and T-help/CTL peptide
JP4628208B2 (ja) *	2004-08-10	2011-02-09	オンコセラピー・サイエンス株式会社	Ｃｘａｄｒｌ１またはｇｃｕｄ１タンパク質を発現する胃癌または結腸直腸癌の治療のためのペプチドワクチン
ES2459466T3 (es) *	2005-02-25	2014-05-09	Oncotherapy Science, Inc.	Vacunas de péptidos para cánceres de pulmón que expresan polipéptidos TTK, URLC10 o KOC1
JP4931154B2 (ja) *	2005-02-28	2012-05-16	オンコセラピー・サイエンス株式会社	血管内皮増殖因子受容体１に由来するエピトープ・ペプチドおよびこれらのペプチドを含むワクチン
US20060234941A1 (en) *	2005-04-15	2006-10-19	The Gov. Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services	Peptide epitopes of VEGFR-2/KDR that inhibit angiogenesis
US7943295B2 (en)	2005-07-29	2011-05-17	Oncotherapy Science, Inc.	Screening and therapeutic method for NSCLC targeting CDCA1-KNTC2 complex
AU2006326405B2 (en)	2005-12-13	2013-10-31	President And Fellows Of Harvard College	Scaffolds for cell transplantation
PL2059256T3 (pl)	2006-08-11	2017-02-28	Life Sciences Research Partners Vzw	Immunogenne peptydy i ich zastosowanie w zaburzeniach immunologicznych
TWI441648B (zh)	2007-01-03	2014-06-21	Oncotherapy Science Inc	Ｆｏｘｐ３胜肽疫苗
JP5470558B2 (ja)	2007-02-16	2014-04-16	オンコセラピー・サイエンス株式会社	脈絡膜新生血管のワクチン療法
TWI434853B (zh) *	2007-04-11	2014-04-21	Oncotherapy Science Inc	腫瘤血管內皮標誌８胜肽及包含此胜肽之疫苗
TW200908998A (en) *	2007-06-27	2009-03-01	Oncotherapy Science Inc	Compositions and methods of treating cancer
US8598125B2 (en) *	2007-08-20	2013-12-03	Onco Therapy Science, Inc.	CDCA1 peptide and pharmaceutical agent comprising the same
MX2010002002A (es)	2007-08-20	2010-03-11	Oncotherapy Science Inc	Peptido foxm1 y agente medicinal que lo contiene.
TWI436775B (zh) *	2007-08-24	2014-05-11	Oncotherapy Science Inc	以抗原胜肽合併化療藥劑治療胰臟癌
TW200932260A (en) *	2007-11-28	2009-08-01	Oncotherapy Science Inc	STAT3 epitope peptides
CA2715460C (en)	2008-02-13	2020-02-18	President And Fellows Of Harvard College	Continuous cell programming devices
WO2009101208A2 (en)	2008-02-14	2009-08-20	Life Sciences Research Partners Vzw	Immunotherapy targeting intracellular pathogens
WO2009101204A2 (en)	2008-02-14	2009-08-20	Life Sciences Research Partners Vzw	Elimination of immune responses to viral vectors
ES2650236T3 (es)	2008-02-14	2018-01-17	Life Sciences Research Partners Vzw	Linfocitos T CD4+ con propiedades citolíticas
US8999346B2 (en)	2008-02-14	2015-04-07	Life Sciences Research Partners Vzw	Immunogenic control of tumours and tumour cells
TW201000119A (en) *	2008-06-10	2010-01-01	Oncotherapy Science Inc	MYBL2 epitope peptides and vaccines containing the same
TWI526219B (zh) *	2008-06-19	2016-03-21	腫瘤療法科學股份有限公司	Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
CA2737040C (en)	2008-09-19	2017-05-02	Nektar Therapeutics	Polymer conjugates of therapeutic peptides
EP2362906B1 (en)	2008-10-22	2015-04-08	Oncotherapy Science, Inc.	Rab6kifl/kif20a epitope peptide and vaccines containing the same
TWI500932B (zh) *	2008-12-05	2015-09-21	Oncotherapy Science Inc	Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗
TW201032820A (en) *	2008-12-16	2010-09-16	Oncotherapy Science Inc	ELOVL7 epitope peptides and vaccines containing the same
RU2011130796A (ru) *	2008-12-24	2013-01-27	Онкотерапи Сайенс, Инк.	Пептиды c1orf59 и содержащие их вакцины
ES2728998T3 (es)	2009-01-08	2019-10-29	Int Inst Cancer Immunology Inc	Nuevo antígeno de cáncer EEF2
AU2010219951A1 (en) *	2009-03-04	2011-08-25	Oncotherapy Science, Inc.	VANGL1 peptides and vaccines including the same
JP5799394B2 (ja) *	2009-03-18	2015-10-28	オンコセラピー・サイエンス株式会社	Ｎｅｉｌ３ペプチドおよびそれを含むワクチン
TW201100090A (en) *	2009-04-01	2011-01-01	Oncotherapy Science Inc	C6orf167 peptides and vaccines containing the same
TWI507204B (zh) *	2009-05-26	2015-11-11	Oncotherapy Science Inc	Ｃｄｃ４５ｌ胜肽與含此胜肽之疫苗
TW201109029A (en)	2009-06-11	2011-03-16	Oncotherapy Science Inc	Vaccine therapy for choroidal neovascularization
JP5926180B2 (ja) *	2009-07-31	2016-05-25	プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ	寛容原性療法のための細胞のプログラミングの方法
TW201200525A (en) *	2009-12-04	2012-01-01	Oncotherapy Science Inc	MYBL2 peptides and vaccines containing the same
TW201136604A (en) *	2009-12-14	2011-11-01	Oncotherapy Science Inc	TMEM22 peptides and vaccines including the same
CN102115492B (zh) *	2010-01-05	2013-03-06	中国农业科学院北京畜牧兽医研究所	血管内皮生长因子受体部分多肽及其应用
EP2545171B1 (en) *	2010-03-11	2017-12-20	OncoTherapy Science, Inc.	Hjurp peptides and vaccines including the same
TW201134480A (en) *	2010-04-08	2011-10-16	Oncotherapy Science Inc	CLUAP1 peptides and vaccines including the same
RU2012147590A (ru) *	2010-04-09	2014-05-20	Онкотерапи Сайенс, Инк.	Пептиды cdca5 и содержащие их вакцины
TW201211250A (en) *	2010-09-07	2012-03-16	Oncotherapy Science Inc	VANGL1 peptides and vaccines including the same
KR102157971B1 (ko)	2010-10-06	2020-09-18	프레지던트 앤드 펠로우즈 오브 하바드 칼리지	재료에 기초한 세포 치료를 위한 주사 가능한 기공 형성 하이드로겔
EP2643345B1 (en)	2010-11-25	2021-02-24	Imnate Sarl	Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination
ES2677118T3 (es)	2010-12-02	2018-07-30	Oncotherapy Science, Inc.	Péptidos de TOMM34 y vacunas que incluyen los mismos
GB201201511D0 (en)	2012-01-30	2012-03-14	Univ Leuven Kath	Modified epitopes for boosting CD4+ T-cell responses
KR20140138900A (ko)	2012-03-09	2014-12-04	온코세라피 사이언스 가부시키가이샤	펩티드를 포함한 의약 조성물
EP3662896B1 (en)	2012-04-16	2024-02-28	President and Fellows of Harvard College	Mesoporous silica compositions for modulating immune responses
JP6263117B2 (ja)	2012-05-11	2018-01-17	公益財団法人微生物化学研究会	抗ｃｘａｄｒ抗体
WO2014010229A1 (en)	2012-07-10	2014-01-16	Oncotherapy Science, Inc.	Cdca1 epitope peptides for th1 cells and vaccines containing the same
RU2015126849A (ru) *	2012-12-04	2017-01-12	Онкотерапи Сайенс, Инк.	Пептиды sema5в и вакцины, содержащие эти пептиды
JP6357113B2 (ja)	2013-02-08	2018-07-11	株式会社医学生物学研究所	ヒトｎｒｇ１タンパク質に対する抗体
GB201309469D0 (en)	2013-05-28	2013-07-10	Imcyse Sa	Detection of CD4+ T lymphocytes
JP2017042047A (ja) *	2013-12-06	2017-03-02	オンコセラピー・サイエンス株式会社	Ｖｅｇｆｒ２由来ペプチドおよびそれを含むワクチン
EP3137105A4 (en)	2014-04-30	2017-12-27	President and Fellows of Harvard College	Combination vaccine devices and methods of killing cancer cells
GB201418433D0 (en)	2014-10-17	2014-12-03	Imcyse Sa	Novel immunogenic peptides
CA3012602A1 (en)	2015-01-30	2016-08-04	President And Fellows Of Harvard College	Peritumoral and intratumoral materials for cancer therapy
JP6604975B2 (ja) *	2015-02-09	2019-11-13	株式会社ライフアートビレッジ	免疫細胞療法のためのペプチドスクリーニング方法
US11150242B2 (en)	2015-04-10	2021-10-19	President And Fellows Of Harvard College	Immune cell trapping devices and methods for making and using the same
US10729791B2 (en)	2015-05-18	2020-08-04	Imcyse Sa	Animal models for evaluating pharmaceutical compounds
US11787849B2 (en)	2015-09-25	2023-10-17	Imcyse Sa	Methods and compounds for eliminating immune responses to therapeutic agents
CN105200010B (zh) *	2015-10-15	2019-02-12	首都医科大学附属北京佑安医院	艾滋病感染者hla-a2特异性ctl细胞的体外培养方法及其专用培养基
CN115531609A (zh)	2016-02-06	2022-12-30	哈佛学院校长同事会	重塑造血巢以重建免疫
JP7320947B2 (ja)	2016-04-19	2023-08-04	アンシス・エスア	新規な免疫原性ＣＤ１ｄ結合ペプチド
US11555177B2 (en)	2016-07-13	2023-01-17	President And Fellows Of Harvard College	Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
JP7168228B2 (ja) *	2017-05-19	2022-11-09	慶應義塾	脳神経疾患に対するペプチドワクチン及びペプチドワクチン組成物
TW202023581A (zh)	2018-08-02	2020-07-01	日商腫瘤療法科學股份有限公司	來自cdca1的胜肽及含有此的疫苗
WO2020061129A1 (en)	2018-09-19	2020-03-26	President And Fellows Of Harvard College	Compositions and methods for labeling and modulation of cells in vitro and in vivo
CN111363026B (zh) *	2020-03-31	2022-03-25	浙江省中医院、浙江中医药大学附属第一医院（浙江省东方医院）	一种增强抗原多肽亲和力和稳定性的方法
KR102711471B1 (ko) *	2020-08-14	2024-09-30	서울대학교산학협력단	B형 간염 바이러스 유래 폴리펩티드를 포함하는 암의 예방 또는 치료용 약학적 조성물

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5861301A (en) *	1992-02-20	1999-01-19	American Cayanamid Company	Recombinant kinase insert domain containing receptor and gene encoding same
US6222012B1 (en)	1992-08-31	2001-04-24	Ludwig Institute For Cancer Research	Isolated nonapeptides presented by HLA molecules, and uses thereof
CN1701814A (zh) *	1992-11-13	2005-11-30	马克斯普朗克科学促进协会	作为血管内皮生长因子受体的f1k－1
JP3734262B2 (ja) *	1993-03-25	2006-01-11	メルクエンドカンパニーインコーポレーテッド	血管内皮細胞増殖因子阻害剤
EP0841945B1 (en)	1995-08-03	2006-03-08	Rijksuniversiteit te Leiden	Cell derived antigen presenting vesicles
US5853719A (en)	1996-04-30	1998-12-29	Duke University	Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US6100071A (en) *	1996-05-07	2000-08-08	Genentech, Inc.	Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6080728A (en)	1996-07-16	2000-06-27	Mixson; A. James	Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
US5942428A (en) *	1996-08-21	1999-08-24	Sugen, Inc.	Crystals of the tyrosine kinase domain of non-insulin receptor tyrosine kinases
DE19638745C2 (de) *	1996-09-11	2001-05-10	Schering Ag	Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
WO1998031794A1 (fr) *	1997-01-17	1998-07-23	Toa Gosei Co., Ltd.	Polypeptide liant le facteur vegf
CA2293723A1 (en) *	1997-06-18	1998-12-23	Merck & Co., Inc.	Human receptor tyrosine kinase, kdr
FR2766205B1 (fr)	1997-07-16	2002-08-30	Inst Nat Sante Rech Med	Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
KR100581508B1 (ko) *	1997-12-05	2006-05-22	가부시키가이샤 그린 펩티드	종양항원 펩티드 유도체
AU2299099A (en) *	1998-02-04	1999-08-23	Kyowa Hakko Kogyo Co. Ltd.	Antibodies against human vegf receptor kdr
GB9804121D0 (en) *	1998-02-26	1998-04-22	Cancer Res Campaign Tech	Anti-angiogenic vaccines: materials and methods relating thereto
AU3850299A (en) *	1998-05-20	1999-12-06	Kyowa Hakko Kogyo Co. Ltd.	Vegf activity inhibitors
ATE375362T1 (de)	1998-06-25	2007-10-15	Kyogo Itoh	Von cyclophilin b abstammende tumorantigen- peptide
WO2001012809A2 (en) *	1999-08-13	2001-02-22	Crucell Holland B.V.	Heterodimeric vegf variants used for inhibiting angiogenesis
US7320793B2 (en)	2001-01-19	2008-01-22	Cytos Biotechnology Ag	Molecular antigen array
JP2002267285A (ja)	2001-03-12	2002-09-18	Denso Corp	冷房冷蔵装置
JP4068371B2 (ja)	2001-06-13	2008-03-26	株式会社トプコン	手術用顕微鏡
JP3640084B2 (ja)	2001-11-30	2005-04-20	日本電気株式会社	測位機能を搭載した携帯電話端末
CU23178A1 (es) *	2002-04-15	2006-09-22	Ct Ingenieria Genetica Biotech	INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
ES2327040T3 (es) *	2002-09-12	2009-10-23	Oncotherapy Science, Inc.	Peptidos kdr y vacunas que los contienen.
ES2428354T3 (es)	2002-09-18	2013-11-07	Trustees Of The University Of Pennsylvania	Rapamicina para usar en la inhibición o prevención de la neovascularización coroidea
JP4931154B2 (ja)	2005-02-28	2012-05-16	オンコセラピー・サイエンス株式会社	血管内皮増殖因子受容体１に由来するエピトープ・ペプチドおよびこれらのペプチドを含むワクチン
JP5470558B2 (ja)	2007-02-16	2014-04-16	オンコセラピー・サイエンス株式会社	脈絡膜新生血管のワクチン療法
TWI436775B (zh)	2007-08-24	2014-05-11	Oncotherapy Science Inc	以抗原胜肽合併化療藥劑治療胰臟癌

2003
- 2003-09-12 ES ES03795432T patent/ES2327040T3/es not_active Expired - Lifetime
- 2003-09-12 CN CNB038250810A patent/CN100352843C/zh not_active Expired - Lifetime
- 2003-09-12 AT AT03795432T patent/ATE432291T1/de active
- 2003-09-12 EP EP10010172.4A patent/EP2261248B1/en not_active Expired - Lifetime
- 2003-09-12 AU AU2003264419A patent/AU2003264419A1/en not_active Abandoned
- 2003-09-12 DK DK10010169.0T patent/DK2267021T3/en active
- 2003-09-12 DE DE60327786T patent/DE60327786D1/de not_active Expired - Lifetime
- 2003-09-12 WO PCT/JP2003/011722 patent/WO2004024766A1/ja active Application Filing
- 2003-09-12 EP EP10010176.5A patent/EP2270042B1/en not_active Expired - Lifetime
- 2003-09-12 PT PT03795432T patent/PT1548032E/pt unknown
- 2003-09-12 EP EP10010174.0A patent/EP2267022B1/en not_active Expired - Lifetime
- 2003-09-12 CN CN2007101802067A patent/CN101139393B/zh not_active Expired - Fee Related
- 2003-09-12 US US10/527,496 patent/US7514084B2/en not_active Expired - Fee Related
- 2003-09-12 PT PT08018875T patent/PT2014678E/pt unknown
- 2003-09-12 EP EP10010175.7A patent/EP2267023B1/en not_active Expired - Lifetime
- 2003-09-12 EP EP10010173.2A patent/EP2261249B1/en not_active Expired - Lifetime
- 2003-09-12 DK DK10010174.0T patent/DK2267022T3/en active
- 2003-09-12 CN CN2007101802052A patent/CN101139392B/zh not_active Expired - Fee Related
- 2003-09-12 DK DK08018875.8T patent/DK2014678T3/da active
- 2003-09-12 EP EP10010171A patent/EP2261247A3/en not_active Withdrawn
- 2003-09-12 ES ES08018875T patent/ES2375299T3/es not_active Expired - Lifetime
- 2003-09-12 DK DK10010175.7T patent/DK2267023T3/en active
- 2003-09-12 EP EP10010169.0A patent/EP2267021B1/en not_active Expired - Lifetime
- 2003-09-12 DK DK03795432T patent/DK1548032T3/da active
- 2003-09-12 AT AT08018875T patent/ATE531729T1/de active
- 2003-09-12 EP EP03795432A patent/EP1548032B9/en not_active Expired - Lifetime
- 2003-09-12 EP EP08018875A patent/EP2014678B1/en not_active Expired - Lifetime
- 2003-09-12 JP JP2004571938A patent/JP3971769B2/ja not_active Expired - Lifetime
- 2003-09-12 EP EP08018897A patent/EP2014679B1/en not_active Expired - Lifetime
- 2003-09-12 EP EP10010170.8A patent/EP2270041B1/en not_active Expired - Lifetime
- 2003-09-12 SI SI200331649T patent/SI1548032T1/sl unknown
- 2003-09-12 CN CN201210430723.6A patent/CN103073620B/zh not_active Expired - Fee Related
- 2003-09-12 SI SI200332101T patent/SI2014678T1/sl unknown
- 2003-09-12 CN CN201410214247.3A patent/CN103951745A/zh active Pending
- 2003-09-12 DK DK10010173.2T patent/DK2261249T3/en active
2007
- 2007-03-08 JP JP2007058127A patent/JP4185143B2/ja not_active Expired - Fee Related
- 2007-05-08 JP JP2007123850A patent/JP4185147B2/ja not_active Expired - Fee Related
2009
- 2009-01-16 US US12/355,616 patent/US7695720B2/en not_active Expired - Lifetime
- 2009-04-30 HK HK09104058.2A patent/HK1124077A1/xx not_active IP Right Cessation
- 2009-05-15 HK HK11104992.7A patent/HK1151036A1/xx not_active IP Right Cessation
- 2009-05-15 HK HK11104995.4A patent/HK1151038A1/xx not_active IP Right Cessation
- 2009-05-15 HK HK11104977.6A patent/HK1151032A1/xx not_active IP Right Cessation
- 2009-05-15 HK HK11104996.3A patent/HK1151039A1/xx not_active IP Right Cessation
- 2009-05-15 HK HK09104475.7A patent/HK1125659A1/xx not_active IP Right Cessation
- 2009-05-15 HK HK11104993.6A patent/HK1151037A1/xx not_active IP Right Cessation
- 2009-08-12 CY CY20091100856T patent/CY1109463T1/el unknown
2010
- 2010-02-23 US US12/711,159 patent/US8206719B2/en not_active Expired - Fee Related
2012
- 2012-01-19 CY CY20121100072T patent/CY1113379T1/el unknown
- 2012-06-12 US US13/494,930 patent/US8574585B2/en not_active Expired - Fee Related
- 2012-06-12 US US13/494,933 patent/US8574586B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
ATE432291T1 (de)	2009-06-15
US20120328636A1 (en)	2012-12-27
ES2327040T3 (es)	2009-10-23
US8206719B2 (en)	2012-06-26
EP2014679B1 (en)	2010-05-05
DK2014678T3 (da)	2012-02-06
CY1113379T1 (el)	2016-06-22
EP2014678B1 (en)	2011-11-02
EP2270042B1 (en)	2015-01-14
EP2267023A3 (en)	2011-02-16
EP2267021A3 (en)	2011-02-16
EP2267023B1 (en)	2015-02-11
DE60327786D1 (de)	2009-07-09
CN100352843C (zh)	2007-12-05
CN101139393B (zh)	2010-11-24
US20130028923A1 (en)	2013-01-31
US20060216301A1 (en)	2006-09-28
EP2267023A2 (en)	2010-12-29
EP2270041A2 (en)	2011-01-05
HK1151036A1 (en)	2012-01-20
CN103073620B (zh)	2014-12-10
JP4185143B2 (ja)	2008-11-26
EP2270041A3 (en)	2011-02-16
ATE531729T1 (de)	2011-11-15
EP1548032A1 (en)	2005-06-29
EP2261248B1 (en)	2015-02-18
US7514084B2 (en)	2009-04-07
PT1548032E (pt)	2009-08-13
EP2267022A2 (en)	2010-12-29
EP2261249B1 (en)	2015-02-11
EP1548032B1 (en)	2009-05-27
EP2261247A2 (en)	2010-12-15
SI2014678T1 (sl)	2012-03-30
DK2261249T3 (en)	2015-02-16
EP2270041B1 (en)	2015-02-25
US8574586B2 (en)	2013-11-05
HK1151039A1 (en)	2012-01-20
EP2014678A3 (en)	2009-03-25
EP2261249A2 (en)	2010-12-15
HK1125659A1 (en)	2009-08-14
CN101139392A (zh)	2008-03-12
EP1548032B9 (en)	2009-10-28
DK2267021T3 (en)	2015-03-30
JPWO2004024766A1 (ja)	2006-01-26
DK2267023T3 (en)	2015-02-23
WO2004024766A1 (ja)	2004-03-25
US20100215676A1 (en)	2010-08-26
JP2007191485A (ja)	2007-08-02
EP2014679A1 (en)	2009-01-14
CN101139392B (zh)	2012-12-26
DK2267022T3 (en)	2015-02-23
EP1548032A4 (en)	2006-03-01
EP2261249A3 (en)	2011-02-16
US8574585B2 (en)	2013-11-05
EP2014678A2 (en)	2009-01-14
EP2261247A3 (en)	2011-02-16
DK1548032T3 (da)	2009-08-17
US20090252752A1 (en)	2009-10-08
EP2267022A3 (en)	2011-02-16
CY1109463T1 (el)	2014-08-13
EP2261248A3 (en)	2011-02-16
EP2270042A2 (en)	2011-01-05
HK1151037A1 (en)	2012-01-20
US7695720B2 (en)	2010-04-13
ES2375299T3 (es)	2012-02-28
EP2261248A2 (en)	2010-12-15
SI1548032T1 (sl)	2009-10-31
HK1124077A1 (en)	2009-07-03
EP2267021A2 (en)	2010-12-29
JP2007277251A (ja)	2007-10-25
JP3971769B2 (ja)	2007-09-05
PT2014678E (pt)	2012-01-05
CN103073620A (zh)	2013-05-01
EP2267022B1 (en)	2015-02-11
EP2270042A3 (en)	2011-02-16
AU2003264419A1 (en)	2004-04-30
EP2267021B1 (en)	2015-02-18
CN103951745A (zh)	2014-07-30
CN1694901A (zh)	2005-11-09
JP4185147B2 (ja)	2008-11-26
HK1151032A1 (en)	2012-01-20
CN101139393A (zh)	2008-03-12

Publication	Publication Date	Title
HK1124077A1 (en)	2009-07-03	Kdr peptides and vaccines comprising the same
WO2006090810A3 (en)	2007-03-29	Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides
HK1134507A1 (en)	2010-04-30	Peptide vaccines for cancers expressing tumor-associated antigens
EP2476697A3 (en)	2013-11-27	Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides
GB0202556D0 (en)	2002-03-20	Novel Protein
DK2289533T3 (da)	2013-12-02	Epitoppeptider afledt af karendothelvækstfaktorreceptor-1 samt vacciner indeholdende disse peptider
ATE495247T1 (de)	2011-01-15	Chromoprotein und fluoroproteine
ATE455792T1 (de)	2010-02-15	Neues phosphatbindendes protein, pharmazeutische zusammensetzungen, die dieses enthalten, und verwendung davon
MX2009007261A (es)	2009-11-11	Vacuna de peptido foxp3.
ATE196926T1 (de)	2000-10-15	Gen grb3-3, variante und ihre verwendungen
MX2010005816A (es)	2010-08-04	Epítopos de péptido de stat3.
DE60336353D1 (de)	2011-04-21	Rekombinantes protein mit krebsunterdrückender wirkung, sein codierendes gen und seine verwendung
EP3219720A3 (en)	2018-01-03	Wdrpuh epitope peptides and vaccines containing the same
WO2002034882A3 (en)	2003-03-20	Genes regulating programmed cell death
CY1114720T1 (el)	2016-10-05	Πεπτιδια επιτοπων που προερχονται απο τον υποδοχεα 1 του αγγειακου ενδοθηλιακου αυξητικου παραγοντα και εμβολια περιεχοντας αυτα τα πεπτιδια

Legal Events

Date	Code	Title	Description
2019-04-18	PC	Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)	Effective date: 20180915